After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
Stocks Info
Biomarin Pharmaceutical Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Biomarin Pharmaceutical Inc is $10.69B. A total of 1.52 million shares were traded on the day, compared to an average of 2.12M shares.
In the most recent transaction, Burkhart Erin sold 1,786 shares of BMRN for 59.31 per share on May 20 ’25. After the transaction, the GVP, Chief Accounting Officer now owns 14,173 company shares. In a previous transaction on May 20 ’25, Burkhart Erin bought 1,786 shares at 59.31 per share.
Among the insiders who sold shares, Hubbard Cristin disposed of 273 shares on May 02 ’25 at a per-share price of $64.92. This resulted in the EVP, Chief Commercial Officer holding 32,700 shares of BMRN after the transaction. In another insider transaction, Hubbard Cristin bought 273 shares at $64.92 per share on May 02 ’25.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, BMRN has a high of $85.64 and a low of $52.93.
As of this writing, BMRN has an earnings estimate of $0.81 per share for the current quarter. EPS was calculated based on a consensus of 18.0 estimates, with a high estimate of $1.17 per share and a lower estimate of -$0.19. The company reported an EPS of $0.91 in the last quarter
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. BMRN’s latest balance sheet shows that the firm has $1.01B in Cash & Short Term Investments as of fiscal 2021. There were $1.09B in debt and $546.50M in liabilities at the time. Its Book Value Per Share was $31.39, while its Total Shareholder’s Equity was $4.27B.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BMRN is Buy with a score of 4.48.
